give without regard to food. • Do not break, crush, dissolve, or divide extended-release tablets.

IM

• Administer 2 initial injections in deltoid muscle (helps attain therapeutic concentration rapidly). • Maintenance doses may be given in gluteal or deltoid muscle.

#####  INDICATIONS/ROUTES/DOSAGE

Treatment of Schizophrenia

**PO:** **ADULTS, ELDERLY:** Initially, 6 mg once daily in the morning. May increase dose in increments of 3 mg/day at intervals of more than 5 days. Range: 3–12 mg/day. **ADOLESCENTS (51 KG OR GREATER):** Initially, 3 mg once daily. Range: 3–12 mg/day. **(50 KG OR LESS):** Initially, 3 mg once daily. Range: 3–6 mg/day.

**IM:** **(Invega Sustenna):** **ADULTS, ELDERLY:** 234 mg on day 1 followed by 156 mg 1 wk later (second dose may be given 4 days before or after the weekly time point). **Maintenance:** Initially, 117nerve impulse conduction, contraction of cardiac, skeletal, smooth muscle; maintains normal renal function, acid-base balance.

#####  PHARMACOKINETICS

Well absorbed from GI tract. Enters cells by active transport from extracellular fluid. Primarily excreted in urine.

#####    ​LIFESPAN CONSIDERATIONS

**Pregnancy/Lactation:** Unknown if drug crosses placenta or is distributed in breast milk. **Pregnancy Category C. Children:** No age-related precautions noted. **Elderly:** May be at increased risk for hyperkalemia. Age-related ability to excrete potassium is reduced.

#####  INTERACTIONS

**DRUG:** **Angiotensin-converting enzyme (ACE) inhibitors, potassium-containing medications, potassium-sparing diuretics, salt substitutes** may increase serum potassium concentration. **HERBAL:** None significant. **FOOD:** None known. **LAB VALUES:** None known.

#####  AVAILABILITY (Rx)

POTASSIUM ACETATE

**Injection, Solution:** 2 mEq/ml.

POTASSIUM BICARBONATE AND POTASSIUM CITRATE

**Tablets for Solution:** **(Effer-K):** 10 mEq, 20 mEq, 25 mEq. **(Klor-Con EF):** 25 mEq.

POTASSIUM CHLORIDE

**Injection, Solution:** 2 mEq/ml. **Oral